In an era where the magnifying glass is firmly focused on viral outbreaks, groundbreaking research led by Caroline Kikawa from the University of Washington has peeled back another layer of the complex interplay between population immunity and the evolution of influenza strains. The study, a fascinating exploration of the role individual immune responses play in […]
Tag: antibody
High Response Rates of Novel Antibody-Drug Conjugate in Rare Blood Cancer Trial
In what can be characterized as a watershed moment in the treatment of rare blood cancers, a novel first-in-class antibody-drug conjugate (ADC), pivekimab sunirine (PVEK), has shattered all expectations in a groundbreaking clinical trial. This innovative therapeutic marvel, marrying the precision of antibodies with the potent cytotoxicity of chemotherapy drugs, has posted an astonishingly high […]
Optimizing Antibody Formulation for Drug Development
In the realm of drug development, the last lap of the race – formulating antibodies – is a Herculean task, akin to threading a microscopic needle while riding a roller coaster. It’s a scientific juggling act requiring the ultimate precision, balance, and control. Christy Eatmon, a global subject matter connoisseur from Thermo Fisher Scientific, reveals […]
Delta-Like Ligand 3 Targeted Therapies Market Overview
The market for delta-like ligand 3 (DLL3) targeted therapies is rapidly expanding due to the rising prevalence of small cell lung cancer (SCLC) and neuroendocrine tumors. Advancements in antibody-drug conjugate (ADC) technology and increased clinical trial activity are driving the development of DLL3-targeted therapies. Strategic collaborations and growing interest from biopharma companies are accelerating market […]
Empaveli Shows Leading Efficacy in Rare Kidney Diseases
In a remarkable breakthrough for rare kidney disease treatment, Apellis and Sobi have demonstrated the potential of Empaveli to exhibit ‘best-in-class’ efficacy. This remarkable development represents a significant stride forward in the field, offering a glimmer of hope for patients grappling with these challenging conditions. Concurrently, Otsuka’s sibeprenlimab is making waves in the same sphere […]
Monoclonal Antibody Lowers Lung Infection Risk
In the realm of biotechnology, the transformative potential of monoclonal antibodies has long been recognized. These laboratory-produced molecules, designed to mimic the immune system’s prowess in combating harmful pathogens, offer a highly targeted approach to preventing infections. A recent study has cast a particularly promising light on these microscopic defenders, revealing their efficacy in mitigating […]
Enhance Antibody Validation with Lysate-Based Over-Expression CellLysate
In the realm of biotechnology, where innovation is the lifeblood of scientific advancement, lysate-based over-expression cell lysate is proving to be a revolutionary tool for validating antibodies. This game-changing methodology, which employs full-length protein overexpression, offers a cost-effective and reliable solution to the longstanding challenges of antibody validation. The technique, which leverages the high-quality antigen […]
Zanidatamab Approval in China
In an unprecedented breakthrough in the realm of targeted therapies, Zymeworks’ zanidatamab has procured conditional approval in China as the inaugural dual HER2-targeted bispecific antibody. This game-changing drug is specifically designed to combat HER2-high expression (IHC3+) biliary tract cancer (BTC), a particularly aggressive form of cancer with few effective treatment options. This milestone was realized […]
C5aR1 as Biomarker for Cutaneous Squamous Cell Carcinoma
The burgeoning field of immuno-oncology has been revolutionized by the promise of targeting the C5a-C5aR1 axis for advanced cutaneous squamous cell carcinoma (cSCC), according to a recent report published in the American Journal of Pathology. The study’s findings have electrified the biotech landscape, suggesting a novel therapeutic approach that could significantly alter the course of […]
Future Growth of Medical Bioreactor Market by 2033
Title: “The Revolution in Medical Bioreactor Market: Platform-Centric Models and Single-Use Configurations Shape Future Trends” The medical bioreactor market stands on the brink of a revolutionary transformation. With the shift towards a platform-centric model that integrates equipment, consumables, and analytics, the industry is poised for an unprecedented leap in efficiency and productivity. This evolution is […]
Bristol Myers Squibb, BioNTech Collaborate on Bispecific Antibody for Solid Tumors
Bristol Myers Squibb and BioNTech have announced a strategic collaboration to co-develop and co-commercialize BNT327, an investigational bispecific antibody for numerous solid tumor types. This ground-breaking partnership aims to leverage BioNTech’s innovative approach to expedite clinical trials, reduce time to market, and explore additional potential indications. Coupled with Bristol Myers Squibb’s renowned expertise in delivering […]
Pharma Boosts R&D Investment Despite Challenges
Despite political and economic challenges, Merck CEO Robert Davis remains optimistic about the company’s ophthalmology business. The recent acquisition of EyeBio brought a $1.3 billion boost, focusing on the trispecific antibody Restoret for diabetic macular edema (DME) and neovascular age-related macular degeneration (AMD). The Phase IIb/III trial for Restoret in DME, known as BRUNELLO, commenced […]
Robust Chronic Kidney Disease Pipeline: 75+ Key Pharma Companies Actively
Ziltivekimab, a proprietary anti-interleukin-6 ligand monoclonal antibody, targets residual inflammatory cardiovascular risk in advanced chronic kidney disease (CKD) patients. Developed as a therapy to reduce major cardiovascular adverse events in CKD patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients with moderate to severe CKD, ASCVD, and inflammation face high cardiovascular event risks with no […]
Innovations in Cancer Therapeutics at ASCO Conference
The Summit Therapeutics study on PD1-VEGF antibody ivonescimab showcased promising results in delaying lung cancer progression among patients. This achievement aligns with prior findings and marks a significant milestone in Phase 3 clinical trials, highlighting advancements in cancer treatment. As the ASCO conference unfolds, these developments underscore the ongoing efforts to combat cancer globally, offering […]
Innovative ANGPTL3-Targeting Therapies for High Cholesterol
Exciting developments in the biotech industry are paving the way for new treatments targeting high cholesterol. Recent studies presented at the American College of Cardiology Scientific Session have shown promising results for ANGPTL3-targeting drugs developed by Eli Lilly and Jiangsu Hengrui Pharmaceuticals. Eli Lilly’s solbinsiran, a small interfering RNA therapy, demonstrated significant reductions in apolipoprotein […]
Innovative Tri-Specific Antibodies for Cancer Immunotherapy
Purple Biotech announces their novel CAPTN-3 tri-specific antibody platform at EACR 2025. The company focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to target multiple cancer indications. NT219, a dual inhibitor small molecule, demonstrated anti-tumor activity in a […]
Cancer Bispecific Antibody Collaboration Accelerates Market Entry
The collaboration between BMS and BioNTech, valued up to $11B, aims to expedite BNT327’s market launch and mitigate risks in various settings. This partnership provides BNTX with non-dilutive capital, fortifying its oncology pipeline. Despite modest overall survival hazard ratios compared to progression-free survival, this deal affirms the asset’s value and enhances BNTX’s financial standing for […]
Aquaporin-4 Antibody Titers Influence Neuromyelitis Optica Relapse
1 In a pivotal and meticulously conducted study involving 171 patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD), researchers have illuminated a powerful new biomarker pathway that could dramatically reshape disease monitoring and therapeutic approaches. The investigation focused on fluctuations in Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody titers — a known hallmark of NMOSD — and […]
